NCT03024671 Epicutaneous Testing of Cosmetics for Skin Compatibility
| NCT ID | NCT03024671 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Dermatitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2017-02-10 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 180 participants in total. It began in 2017-02-10 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The dermatological testing of cosmetic products which are new on the market, or existing products with novel formulations is common and a useful procedure, yet necessary to alleviate common irritants and contact allergic reactions. Cosmetic products contain a range of substances that may be considered as potential irritants or contact allergens. In order to estimate that risk, cosmetics are tested by applying patch tests.
Eligibility Criteria
Inclusion Criteria: * Men and women older than 18 years old * Persons undergoing a diagnostic patch test for reason of a skin disease * Signed written informed consent Exclusion Criteria: * Acute skin inflammation and eczema on the back * Systemic corticosteroid and immunosuppressive therapy as well as UV exposure of the back within the last 4 weeks * Topical corticosteroids used on the back within the last two weeks
Contact & Investigator
Dagmar Simon, MD
PRINCIPAL INVESTIGATOR
Dept. of Dermatology, Inselspital
Frequently Asked Questions
Who can join the NCT03024671 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03024671 currently recruiting?
Yes, NCT03024671 is actively recruiting participants. Contact the research team at dagmar.simon@insel.ch for enrollment information.
Where is the NCT03024671 trial being conducted?
This trial is being conducted at Bern, Switzerland.
Who is sponsoring the NCT03024671 clinical trial?
NCT03024671 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Dagmar Simon, MD at Dept. of Dermatology, Inselspital. The trial plans to enroll 180 participants.